Sep 23, 2025 | News, Press Release
Seattle, WA — September 23, 2025 – Kayothera, Inc. (“Kayothera”), a preclinical therapeutics company developing first-in-class, small molecule inhibitors of the retinoid nuclear receptor pathway, today announces that it has selected KAYO-1732 as a drug development... Jun 21, 2025 | News, Press Release
Seattle, WA — June 21, 2025, Kayothera, Inc., a preclinical-stage therapeutics company pioneering first-in-class, oral inhibitors of the retinoid nuclear receptor pathway, today announced that it has been recognized as one of the winners of the American Diabetes... Oct 22, 2024 | News, Press Release
Yibin Kang, PhD, chairs Scientific Advisory Board that includes experts in translational and early-phase clinical development activities Seattle, WA — October 22, 2024, Kayothera, Inc., a preclinical-stage therapeutics company developing first-in-class, oral, small... Oct 14, 2024 | News, Press Release
Bruce L.A. Carter, PhD, and Paul Sekhri join Board of Directors, adding drug development and operating experience Recent board additions highlight Kayothera’s evolution into pipeline-focused organization with meaningful translational efforts Seattle, WA —... Sep 18, 2023 | News, Press Release
Unique safety profile positions KAYO-1609 as the first retinoid pathway inhibitor to enter Investigational New Drug (IND)-enabling studies Company expects to file IND application with the U.S. Food & Drug Administration (FDA) by the end of 2024 Seattle, WA —... Jul 19, 2023 | News, Press Release
New funding comprised of grants from the National Institutes of Health, The Andy Hill Cancer Research Endowment (CARE) Fund, and additional Equity Funding Additional funding will support advancement of KayoThera’s development programs in diabetes and oncology...